SurModics Showcases Drug Delivery Technology at The 37th Annual
Meeting and Exposition of the Controlled Release Society

July 9, 2010 at 10:00 AM EDT

EDEN PRAIRIE, Minn., Jul 09, 2010 (BUSINESS WIRE) --

SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, is participating at the 37th Annual Meeting and Exposition of the Controlled Release Society (CRS), July 10-14, 2010 in Portland, Oregon (booth #521). SurModics announced that it is presenting four scientific posters on its drug delivery technologies:

  • Peter Markland, Ph.D, Director of New Technologies, is presenting Sustained Release Microparticle Formulations Administered Through Small-Bore Needles Useful for Intraocular Applications (poster 237) on Monday, July 12 from 1:00-2:00 PM. The poster describes novel microparticle compositions that can be administered through smaller-diameter needles than standard biodegradable microparticle formulations. These novel compositions allow for administration using smaller gauge needles which can improve patient compliance, especially for routes of administration that are particularly sensitive to needle diameter such as ocular delivery.
  • Parissa Heshmati, Ph.D, Senior Scientist, is presenting Use of Anionic and Cationic Surfactants in Poly(Lactide-co-Glycolide) Nanoparticle Production (poster 337) on Monday, July 12 from 1:00-2:00 PM. The poster demonstrates the use of a variety of anionic and cationic surface active agents replacing the widely used poly(vinyl alcohol) surfactant in nanoparticle production.
  • Joram Slager, Ph.D, Staff Scientist, is presenting Long Term Protein Delivery from Organogel Formulations (poster 379) on Monday, July 12 from 1:00-2:00 PM. The poster shows long term and tunable release of antibodies from an in situ gelling delivery system based on SurModics' EurekaTM SOLO polymer platform. These hydrophobic gels, either physically or chemically crosslinked, have the advantage of a relative ease of administration and the potential for incorporating high pay-loads of therapeutic proteins.
  • Joe McGonigle, Ph.D, Senior Engineer, is presenting Controlled Release of Bioactive Cationic Lipid/siRNA Complexes from Implantable and Injectable Hydrogel Matrices (poster 635) on Tuesday, July 13 from 1:00-2:00 PM. The poster demonstrates that SurModics' EurekaTM DUET polymer platform can be used for sustained release of cationic lipid/siRNA complexes which retain high levels of gene knockdown activity.

"These posters demonstrate SurModics' innovative drug delivery technologies, enabling delivery in new therapeutic areas and improved routes of administration. Additionally, they showcase our expertise in delivering novel therapeutic classes such as proteins and siRNA," said Phil Ankeny, Interim CEO. "As a leader in drug delivery and surface modification technologies, SurModics is committed to providing proven technologies to our partners and to helping accelerate the commercialization process with clinically important products."

SurModics conducts research, development, and manufacturing of specialty polymers and other biomaterials for parenteral drug delivery products.

To learn more about SurModics' partnership programs for drug delivery product development, as well as its technology portfolio, world class R&D and clinical and commercial manufacturing services, please visit booth #521 at CRS 2010.

About SurModics, Inc.

SurModics' vision is to extend and improve the lives of patients through technology innovation. The Company partners with the world's foremost medical device, pharmaceutical and life science companies to develop and commercialize innovative products that result in improved diagnosis and treatment for patients. Core offerings include: drug delivery technologies (coatings, microparticles, nanoparticles, and implants); surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for in vitro diagnostic test kits and specialized surfaces for cell culture and microarrays. SurModics is headquartered in Eden Prairie, Minnesota and its SurModics Pharmaceuticals subsidiary is located in Birmingham, Alabama. For more information about the Company, visit The content of SurModics' website is not part of this release or part of any filings the Company makes with the SEC.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements. Statements that are not historical or current facts, including statements about beliefs and expectations, such as those regarding the ability of our partners to commercialize products using our technologies, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including those identified under "Risk Factors" in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2009, and updated in our subsequent reports filed with the SEC. These reports are available in the Investors section of our website at and at the SEC website at Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.

SOURCE: SurModics, Inc.

SurModics, Inc.
Phil Ankeny, Interim CEO, Senior VP and CFO
(952) 829-2700